Literature DB >> 2414612

Early peritoneal mesothelioma: a treatable malignancy.

K H Antman, R T Osteen, K L Klegar, D A Amato, E A Pomfret, D A Larson, J M Corson.   

Abstract

37 patients with malignant peritoneal mesothelioma were studied to assess the efficacy of combined therapy. 14 patients presented after 1982. Of 6 patients treated intensively, all remain alive with no evidence of disease by computed tomographic scan at 9-36 months. Of 8 patients treated palliatively, 5 are dead. (5 had stable disease, 1 has progressed despite all treatment, and 2 were not treated.) Survival of the intensively treated group is significantly better than that of other stage I patients in this series. Patients under 40 had a significantly better survival rate than older patients.

Entities:  

Mesh:

Year:  1985        PMID: 2414612     DOI: 10.1016/s0140-6736(85)90526-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  15 in total

Review 1.  Malignant mesothelioma.

Authors:  R Rudd
Journal:  J R Soc Med       Date:  1989-03       Impact factor: 5.344

Review 2.  Chemotherapy in malignant mesothelioma: a review.

Authors:  A Krarup-Hansen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  A novel nomogram for peritoneal mesothelioma predicts survival.

Authors:  Nicholas P Schaub; Meghna Alimchandani; Martha Quezado; Phil Kalina; John S Eberhardt; Marybeth S Hughes; Tatiana Beresnev; Raffit Hassan; David L Bartlett; Steven K Libutti; James F Pingpank; Richard E Royal; Udai S Kammula; Prakash Pandalai; Giao Q Phan; Alexander Stojadinovic; Udo Rudloff; H Richard Alexander; Itzhak Avital
Journal:  Ann Surg Oncol       Date:  2012-12-12       Impact factor: 5.344

4.  Peritoneal mesothelioma.

Authors:  J H Anderson; C J Stewart; D T Hansell; J R Anderson
Journal:  Postgrad Med J       Date:  1990-10       Impact factor: 2.401

5.  Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone.

Authors:  L T Vlasveld; B G Taal; B B Kroon; M P Gallee; S Rodenhuis
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma.

Authors:  Sheelu Varghese; Zhaorong Chen; David L Bartlett; James F Pingpank; Steven K Libutti; Seth M Steinberg; John Wunderlich; H Richard Alexander
Journal:  Cancer       Date:  2010-09-13       Impact factor: 6.860

Review 7.  Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management.

Authors:  Terence C Chua; Tristan D Yan; David L Morris
Journal:  Can J Surg       Date:  2009-02       Impact factor: 2.089

8.  The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.

Authors:  Aatur D Singhi; Alyssa M Krasinskas; Haroon A Choudry; David L Bartlett; James F Pingpank; Herbert J Zeh; Alyssa Luvison; Kimberly Fuhrer; Nathan Bahary; Raja R Seethala; Sanja Dacic
Journal:  Mod Pathol       Date:  2015-10-23       Impact factor: 7.842

Review 9.  Peritoneal mesothelioma.

Authors:  R N Taub; M L Keohan; J C Chabot; K S Fountain; M Plitsas
Journal:  Curr Treat Options Oncol       Date:  2000-10

10.  Surgical treatment of malignant peritoneal mesothelioma: past, present, and future.

Authors:  H Richard Alexander
Journal:  Ann Surg Oncol       Date:  2010-01       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.